HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a $20 price target, as stated by analyst Joseph Pantginis.
August 12, 2024 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics and maintained a $20 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Aprea Therapeutics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100